West Family Investments Inc. Invests $251,000 in argenx SE (NASDAQ:ARGX)

West Family Investments Inc. acquired a new position in shares of argenx SE (NASDAQ:ARGX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 408 shares of the company’s stock, valued at approximately $251,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ARGX. Callan Family Office LLC acquired a new stake in shares of argenx in the fourth quarter valued at approximately $396,000. Raymond James Financial Inc. bought a new position in argenx in the fourth quarter valued at $43,543,000. Assetmark Inc. increased its stake in argenx by 11.3% in the 4th quarter. Assetmark Inc. now owns 8,648 shares of the company’s stock valued at $5,319,000 after buying an additional 879 shares during the last quarter. J.Safra Asset Management Corp lifted its position in argenx by 123.8% during the 4th quarter. J.Safra Asset Management Corp now owns 273 shares of the company’s stock worth $169,000 after buying an additional 151 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in argenx by 21.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,214 shares of the company’s stock worth $2,592,000 after buying an additional 755 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Price Performance

Shares of NASDAQ ARGX opened at $594.21 on Friday. argenx SE has a one year low of $349.86 and a one year high of $678.21. The firm has a market cap of $36.10 billion, a price-to-earnings ratio of -675.24 and a beta of 0.58. The stock’s fifty day moving average price is $642.09 and its two-hundred day moving average price is $593.03.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Piper Sandler lifted their target price on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. William Blair reiterated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft cut shares of argenx from a “hold” rating to a “sell” rating in a research note on Friday, January 17th. HC Wainwright boosted their target price on shares of argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Wedbush restated an “outperform” rating and set a $655.00 price objective on shares of argenx in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, argenx currently has an average rating of “Moderate Buy” and an average price target of $662.83.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.